NEW YORK, July 31 - SurroMed and Japanese genomics service company MediBic will co-develop biomarkers for drug discovery, the companies said today.
Terms of the deal also call for Tokyo-based MediBic to exclusively sell the biomarkers in Japan.
"We are confident that [MediBic's] ... record and their longstanding relationships will enable us to expand the market in Japan," said SurroMed CEO Gordon Ringold.
SurroMed's biomarker-discovery program pairs sample-preparation techniques with mass spectrometry. SurroMed then uses bioinformatics tools to analyze and mine the data.
MediBic has "relationships" with more than 20 Japanese pharmaceutical and biotechnology companies, according to the company.